Long-Term Cost-Effectiveness Analysis of Once-Weekly Semaglutide versus Dulaglutide in Patients with Type 2 Diabetes with Inadequate Glycemic Control in China.

Zhen RuanCarolina Oi Lam UngYang ShenYawen ZhangWeihao WangJingyi LuoHuimin ZouYan XueYao WangHao HuLixin Guo

Published in: Diabetes therapy : research, treatment and education of diabetes and related disorders (2022)

Once-weekly semaglutide was suggested to be dominant (more effective and less costly) versus dulaglutide 1.5 mg in patients with type 2 diabetes uncontrolled on metformin treatment in China.

Keyphrases

glycemic control
type diabetes
blood glucose
weight loss
adipose tissue
metabolic syndrome